{
    "nct_id": "NCT05363293",
    "title": "A Multiple-dose, Steady-state, Double-blind, Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Mild to Moderate Alzheimer's Disease and Healthy Adult Subjects (\"MAD Study\")",
    "status": "COMPLETED",
    "last_update_time": "2025-04-25",
    "description_brief": "This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.",
    "description_detailed": "This is a Phase 1/2a, multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose (MTD) of AL001, a crystal engineered lithium-salicylate-proline lithium delivery product that in nonclinical studies was shown to enhance and prolong the pharmacokinetic (PK) profile of lithium in the brain with enhanced efficacy potential in Alzheimer's models compared to lithium carbonate.\n\nA maximum of approximately 72 participants will be enrolled. Participants will be randomly assigned to receive study drug (active AL001) or placebo in a ratio of 6:2, respectively, with 8 patients in each dosing cohort. Placebos will be pooled and regarded as a comparative cohort for safety.\n\nCohorts 2a, 3a, 4a and 5a will involve 1:1 healthy non-elderly and elderly subjects; cohorts 1, 2b, 3b, 4b and 5b will involve Alzheimer's subjects. The study will consist of a screening period (Days -28 to -2), a 14-day treatment period, and a 42-day follow-up period.",
    "phase": [
        "PHASE1",
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "There were no pre-specified comparisons between healthy controls and AD patients.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 1",
                    "description": "AD-only participants (no normal healthy subjects) were randomized to receive AL001. When adequate safety data were available, a review was done for all participants to make a dose-escalation or dose and/or regimen modification decision. This was repeated for each cohort.\n\nA total of 8 cohorts received 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.\n\nCohort 1 included 6 AD subjects only (7 were randomized because 1 subject voluntarily withdrew before dosing); 6 active AD subjects (as per randomization code) received the following treatment or placebo:\n\n\u2022 Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily \u00d714 days, given as 3 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG001",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 2a",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 2a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults). Blinded results from Cohort 2a were reviewed by the safety review committee before Cohort 2b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID).\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG002",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 2b",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 2b (6 AD subjects). Blinded results from Cohort 2a were reviewed by the safety review committee before Cohort 2b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID).\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG003",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 3a",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 3a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults). Blinded results from Cohort 3a were reviewed by the safety review committee before Cohort 3b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 3a: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG004",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 3b",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 3b (6 AD subjects). Blinded results from Cohort 3a were reviewed by the safety review committee before Cohort 3b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG005",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 4a",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 4a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults). Blinded results from Cohort 4a were reviewed by the safety review committee before Cohort 4b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG006",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 4b",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 4b (6 AD subjects). Blinded results from Cohort 4a were reviewed by the safety review committee before Cohort 4b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG007",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 5a",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 5 was planned to be divided into 2 sub-cohorts: Cohort 5a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 5b (8 AD subjects).\n\nPer randomization, there were 6 active normal healthy subjects in cohort 5a. Stopping rules were invoked by the Safety Committee due to the pharmacokinetic results of Cohort 5a. The Stopping Rules were not invoked due to any adverse event. The stopping criteria were modest increases in plasma levels of lithium and salicylate above what is reported in the literature as the maximum therapeutic range concentrations.\n\n\u2022 Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG008",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 5b",
                    "description": "Subjects for Cohort 5b (6 AD subjects) were not enrolled because the Safety Committee invoked study stopping rules.\n\nPer randomization, there were 6 active normal healthy subjects in cohort 5a. Stopping rules were invoked by the Safety Committee due to the pharmacokinetic results of Cohort 5a. The Stopping Rules were not invoked due to any adverse event. The stopping criteria were modest increases in plasma levels of lithium and salicylate above what is reported in the literature as the maximum therapeutic range concentrations.\n\n\u2022 Cohort 5b was not dosed. Subjects would have been dosed at 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "FG009",
                    "title": "Combined Placebo Group",
                    "description": "2 subjects were randomized to receive matching placebo (no active drug) concurrently with each of the 8 treatment cohorts. A total of 16 subjects receiving placebo were combined in 1 group."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "7"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG005",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG006",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG007",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG008",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG009",
                                    "numSubjects": "16"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG005",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG006",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG007",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG008",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG009",
                                    "numSubjects": "16"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG005",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG006",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG007",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG008",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG009",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG005",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG006",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG007",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG008",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG009",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "Cohort 1 (AD subject), n=6 randomized to AL001(1 withdrawal before dosing). Cohort 2a (healthy volunteers \\[HV\\]): n=6 rand. to AL001. Cohort 2b (AD): n=6 rand. to AL001.\n\nCohort 3a (HV): n=6 rand. to AL001. Cohort 3b (AD): n=6 rand. to AL001. Cohort 4a (HV): n=6 rand. to AL001. Cohort 4b (AD): n=6 rand. to AL001. Cohort 5 (HV), n=6 rand. to AL001. Combined Placebo Group, n=16.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "Multiple Ascending Doses of AL001- Cohort 1 (1890 mg AL001/d, 630mg TID \u00d714 Days)",
                    "description": "AD-only participants (no normal healthy subjects) were randomized to receive AL001. When adequate safety data were available, a review was done for all participants to make a dose-escalation or dose and/or regimen modification decision. This was repeated for each cohort.\n\nA total of 8 cohorts received 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.\n\nCohort 1 included 6 AD subjects only (7 were randomized because 1 subject voluntarily withdrew before dosing); 6 active AD subjects (as per randomization code) received the following treatment:\n\n\u2022 Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily \u00d714 days, given as 3 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG001",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 2a (3150 mg AL001/d, 1050mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 2 was divided into 2 sub-cohorts: Cohort 2a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 2b (6 AD subjects). Blinded results from Cohort 2a were reviewed by the safety review committee before Cohort 2b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID).\n\nAL001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG002",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 2b (3150 mg AL001/d, 1050mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 2 was divided into 2 sub-cohorts: Cohort 2a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 2b (8 AD subjects). Blinded results from Cohort 2a were reviewed by the safety review committee before Cohort 2b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID).\n\nAL001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG003",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 3a (4410 mg AL001/d, 1470mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 3 was divided into 2 sub-cohorts: Cohort 3a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 3b (6 AD subjects). Blinded results from Cohort 3a were reviewed by the safety review committee before Cohort 3b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 3a: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG004",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 3b (4410 mg AL001/d, 1470mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 3 was divided into 2 sub-cohorts: Cohort 3a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 3b (6 AD subjects). Blinded results from Cohort 3a were reviewed by the safety review committee before Cohort 3b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG005",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 4a (5040 mg AL001/d, 1680mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 4 was divided into 2 sub-cohorts: Cohort 4a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 4b (6 AD subjects). Blinded results from Cohort 4a were reviewed by the safety review committee before Cohort 4b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG006",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 4b (5040 mg AL001/d, 1680mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 4 was divided into 2 sub-cohorts: Cohort 4a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 4b (6 AD subjects). Blinded results from Cohort 4a were reviewed by the safety review committee before Cohort 4b was randomized. Per randomization, there were 6 active subjects in each cohort:\n\n\u2022 Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG007",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 5a (6300 mg AL001/d, 2100mg TID \u00d7 14 Days)",
                    "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 5 was planned to be divided into 2 sub-cohorts: Cohort 5a (6 healthy subjects - 3 non-elderly adults and 3 elderly adults) and Cohort 5b (6 AD subjects).\n\nPer randomization, there were 6 active normal healthy subjects in cohort 5a. Stopping rules were invoked by the Safety Committee due to the pharmacokinetic results of Cohort 5a. The Stopping Rules were not invoked due to any adverse event. The stopping criteria were modest increases in plasma levels of lithium and salicylate above what is reported in the literature as the maximum therapeutic range concentrations.\n\n\u2022 Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG008",
                    "title": "Multiple Ascending Doses of AL001 - Cohort 5b (6300 mg AL001/d, 2100mg TID \u00d7 14 Days)",
                    "description": "Subjects for Cohort 5b (6 AD subjects) were not enrolled because the Safety Committee invoked study stopping rules due to the pharmacokinetic results of Cohort 5a. The Stopping Rules were not invoked due to any adverse event. The stopping criteria were modest increases in plasma levels of lithium and salicylate above what is reported in the literature as the maximum therapeutic range concentrations.\n\n\u2022 Cohort 5b was not dosed. Subjects would have been dosed at 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product."
                },
                {
                    "id": "BG009",
                    "title": "Combined Placebo Group",
                    "description": "2 subjects were randomized to receive matching placebo (no active drug) concurrently with each of the 8 treatment cohorts. A total of 16 subjects receiving placebo were combined in 1 group."
                },
                {
                    "id": "BG010",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "7"
                        },
                        {
                            "groupId": "BG001",
                            "value": "6"
                        },
                        {
                            "groupId": "BG002",
                            "value": "6"
                        },
                        {
                            "groupId": "BG003",
                            "value": "6"
                        },
                        {
                            "groupId": "BG004",
                            "value": "6"
                        },
                        {
                            "groupId": "BG005",
                            "value": "6"
                        },
                        {
                            "groupId": "BG006",
                            "value": "6"
                        },
                        {
                            "groupId": "BG007",
                            "value": "6"
                        },
                        {
                            "groupId": "BG008",
                            "value": "0"
                        },
                        {
                            "groupId": "BG009",
                            "value": "16"
                        },
                        {
                            "groupId": "BG010",
                            "value": "65"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Customized",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "63.1",
                                            "lowerLimit": "56",
                                            "upperLimit": "71"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "65.4",
                                            "lowerLimit": "52",
                                            "upperLimit": "77"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "65.4",
                                            "lowerLimit": "52",
                                            "upperLimit": "77"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "57.5",
                                            "lowerLimit": "24",
                                            "upperLimit": "72"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "57.5",
                                            "lowerLimit": "24",
                                            "upperLimit": "72"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "58.8",
                                            "lowerLimit": "32",
                                            "upperLimit": "74"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "58.8",
                                            "lowerLimit": "32",
                                            "upperLimit": "74"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "57.3",
                                            "lowerLimit": "33",
                                            "upperLimit": "70"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "59.4",
                                            "lowerLimit": "24",
                                            "upperLimit": "75"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "60.2",
                                            "lowerLimit": "24",
                                            "upperLimit": "77"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "34"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "31"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "28"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "37"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Ratio of Plasma Lithium trough >1.0mEq/L or plasma salicylate peak concentrations >30mg/dL",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "ratio",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG009",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG010",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.",
                    "description": "To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following:\n\nProportion of participants with treatment-emergent adverse events (TEAEs)\n\n* Proportion of participants with serious AEs\n* Proportion of participants with TEAEs that lead to premature discontinuation\n* Proportion of participants with abnormal values for each safety laboratory test (change from baseline)\n* Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters)\n\nFor all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.",
                    "populationDescription": "All subjects in the Randomized Analysis Set who received any dose of the study drug. This analysis set was used for all safety analyses.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "42 days with a 14-day treatment period",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1",
                            "description": "AD-only participants (no normal healthy subjects) were randomized to receive AL001. When adequate safety data were available, a review was done for all participants to make a dose-escalation or dose and/or regimen modification decision. This was repeated for each cohort.\n\nA total of 8 cohorts received 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.\n\nCohort 1 included 8 AD subjects only (9 were randomized because 1 subject voluntarily withdrew before dosing); 6 active and 2 placebo AD subjects (as per randomization code) received the following treatment or placebo:\n\n\u2022 Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily \u00d714 days, given as 3 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG001",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2a",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 2 was divided into 2 sub-cohorts: Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 2b (8 AD subjects). Blinded results from Cohort 2a were reviewed by the safety review committee before Cohort 2b was randomized. Per randomization, there were 6 active and 2 placebo subjects in each cohort:\n\n\u2022 Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID).\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG002",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2b",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 2 was divided into 2 sub-cohorts: Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 2b (8 AD subjects). Blinded results from Cohort 2a were reviewed by the safety review committee before Cohort 2b was randomized. Per randomization, there were 6 active and 2 placebo subjects in each cohort:\n\n\u2022 Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID).\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG003",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 3 was divided into 2 sub-cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Blinded results from Cohort 3a were reviewed by the safety review committee before Cohort 3b was randomized. Per randomization, there were 6 active and 2 placebo subjects in each cohort:\n\n\u2022 Cohort 3a: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG004",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 3 was divided into 2 sub-cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Blinded results from Cohort 3a were reviewed by the safety review committee before Cohort 3b was randomized. Per randomization, there were 6 active and 2 placebo subjects in each cohort:\n\n\u2022 Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG005",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 4 was divided into 2 sub-cohorts: Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 4b (8 AD subjects). Blinded results from Cohort 4a were reviewed by the safety review committee before Cohort 4b was randomized. Per randomization, there were 6 active and 2 placebo subjects in each cohort:\n\n\u2022 Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG006",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 4 was divided into 2 sub-cohorts: Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 4b (8 AD subjects). Blinded results from Cohort 4a were reviewed by the safety review committee before Cohort 4b was randomized. Per randomization, there were 6 active and 2 placebo subjects in each cohort:\n\n\u2022 Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG007",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a",
                            "description": "The data from the previous cohort were deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 5 was planned to be divided into 2 sub-cohorts: Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 5b (8 AD subjects).\n\nPer randomization, there were 6 active and 2 placebo normal healthy subjects in cohort 5a. Stopping rules were invoked by the Safety Committee due to the pharmacokinetic results of Cohort 5a. The Stopping Rules were not invoked due to any adverse event. The stopping criteria were modest increases in plasma levels of lithium and salicylate above what is reported in the literature as the maximum therapeutic range concentrations.\n\n\u2022 Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID).\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG008",
                            "title": "Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b",
                            "description": "Subjects for Cohort 5b (8 AD subjects) were not enrolled because the Safety Committee invoked study stopping rules due to the pharmacokinetic results of Cohort 5a. The Stopping Rules were not invoked due to any adverse event. The stopping criteria were modest increases in plasma levels of lithium and salicylate above what is reported in the literature as the maximum therapeutic range concentrations.\n\n\u2022 Cohort 5b was not dosed. Subjects would have been dosed at 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation."
                        },
                        {
                            "id": "OG009",
                            "title": "Multiple Ascending Doses of AL001 - Pooled Placebo Group",
                            "description": "This is a Cohort which is a composite of all 16 placebo-treated participants derived from all recruited Cohorts.\n\nPlacebo: matching placebo formulation"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG005",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG006",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG007",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG008",
                                    "value": "0"
                                },
                                {
                                    "groupId": "OG009",
                                    "value": "16"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Serious AEs",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG008",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG009",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "TEAEs that lead to premature discontinuation",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG009",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Abnormal values for safety laboratory tests (change from baseline)",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG009",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "abnormal ECG parameters (change from baseline)",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG009",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "No Adverse Events observed",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG009",
                                            "value": "16"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001",
                    "description": "To characterize the MTD of AL001 in all subjects treated with AL001:\n\n\u2022 Proportion of subjects in each Cohort with plasma trough measurements of lithium \\> 1.0 mEq/L. Subjects above these values invoke stopping rules for subsequent cohort enrollment.",
                    "populationDescription": "All subjects in the Safety Analysis Set who received AL001 and had a trough measurement for lithium.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Proportion of Subjects",
                    "timeFrame": "42 days with a 14-day treatment period",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 1",
                            "description": "Participants were randomized to receive AL001.\n\nCohort 1 included 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) received the following treatment or placebo:\n\n\u2022 Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily \u00d714 days, given as 3 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG001",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 2a",
                            "description": "Steady State Assessment for Trough Plasma Lithium Concentrations\n\n\u2022 Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID)."
                        },
                        {
                            "id": "OG002",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 2b",
                            "description": "Steady State Assessment for Trough Plasma Lithium Concentrations\n\n\u2022 Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID)."
                        },
                        {
                            "id": "OG003",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 3a",
                            "description": "Steady State Assessment for Trough Plasma Lithium Concentrations\n\n\u2022 Cohort 3a: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG004",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 3b",
                            "description": "Steady State Assessment for Trough Plasma Lithium Concentrations\n\n\u2022 Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG005",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 4a",
                            "description": "Steady State Assessment for Trough Plasma Lithium Concentrations\n\n\u2022 Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG006",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 4b",
                            "description": "Steady State Assessment for Trough Plasma Lithium Concentrations\n\n\u2022 Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG007",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 5a",
                            "description": "The data from the previous cohort had to be deemed safe before the next sequential cohort was enrolled and dosing initiated.\n\nCohort 5 was planned to be divided into 2 sub-cohorts: Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 5b (8 AD subjects).\n\nModestly higher than threshold lithium plasma concentrations were observed in Cohort 5a and can be expected to occur in AD subjects. It was decided to not run Cohort 5b.\n\n\u2022 Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG008",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 5b",
                            "description": "Cohort 5b was not dosed, because the Safety Committee invoked study stopping rules that were not due to AEs.\n\nIt was decided to not run Cohort 5b."
                        },
                        {
                            "id": "OG009",
                            "title": "Multiple Ascending Doses of AL001 - Pooled Placebo Group",
                            "description": "This is a Cohort which is a composite of all 16 placebo-treated participants derived from all recruited Cohorts.\n\nPlacebo: matching placebo formulation"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG005",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG006",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG007",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG008",
                                    "value": "0"
                                },
                                {
                                    "groupId": "OG009",
                                    "value": "16"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "0.167"
                                        },
                                        {
                                            "groupId": "OG009",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects",
                    "description": "To characterize the MTD of AL001 in all subjects:\n\n\u2022 Proportion of all subjects with plasma maximum concentration (Cmax) measurements for salicylate \\> 30 mg/dL",
                    "populationDescription": "All subjects in the Safety Analysis Set who received AL001 and had a Cmax measurement for salicylate.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Proportion of Subjects",
                    "timeFrame": "42 days with a 14-day treatment period",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 1",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations.\n\nNo healthy subjects were enrolled in Cohort 1. AD Subjects were randomized to receive AL001.\n\nCohort 1 included 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) received the following treatment or placebo:\n\n\u2022 Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily \u00d714 days, given as 3 \u00d7 210 mg AL001 capsules TID)\n\nAL 001: a crystal engineered lithium-salicylate-proline lithium delivery product\n\nPlacebo: matching placebo formulation"
                        },
                        {
                            "id": "OG001",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 2a",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations\n\n\u2022 Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID)."
                        },
                        {
                            "id": "OG002",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 2b",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations\n\n\u2022 Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID)."
                        },
                        {
                            "id": "OG003",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 3a",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations\n\n\u2022 Cohort 3a: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG004",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 3b",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations\n\n\u2022 Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG005",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 4a",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations\n\n\u2022 Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG006",
                            "title": "Multiple Ascending Doses of AL001 in AD Subjects - Cohort 4b",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations\n\n\u2022 Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG007",
                            "title": "Multiple Ascending Doses of AL001 in Healthy Subjects - Cohort 5a",
                            "description": "Steady State Assessment for Peak Plasma Salicylate Concentrations.\n\nBased on the data from Cohort 5a suggested the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.\n\nIt was decided by the safety committee based on stopping rules to not run Cohort 5b.\n\n\u2022 Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID)"
                        },
                        {
                            "id": "OG008",
                            "title": "Multiple Ascending Doses of AL001 - Pooled Placebo Group",
                            "description": "This is a Cohort which is a composite of all 16 placebo-treated participants derived from all recruited Cohorts.\n\nPlacebo: matching placebo formulation"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG005",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG006",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG007",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG008",
                                    "value": "16"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG006",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG007",
                                            "value": "0.167"
                                        },
                                        {
                                            "groupId": "OG008",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "42 days with a 14 day treatment period per cohort (phone call follow-up on day 42 to confirm safety)",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "AD in Cohort 1",
                    "description": "Subject w/AD randomized to 1890 mg AL001 daily \u00d714 days, given as 3 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG001",
                    "title": "AD on Cohort 2",
                    "description": "Subject w/AD randomized to 3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG002",
                    "title": "AD in Cohort 3",
                    "description": "Subject w/AD randomized to 4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG003",
                    "title": "AD in Cohort 4",
                    "description": "Subject w/AD randomized to 5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG004",
                    "title": "Healthy Subjects in Cohort 2",
                    "description": "Healthy Subject randomized to 3150 mg AL001 daily \u00d7 14 days, given as 5 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 3,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG005",
                    "title": "Healthy Subjects in Cohort 3",
                    "description": "Healthy Subject randomized to 4410 mg AL001 daily \u00d7 14 days, given as 7 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG006",
                    "title": "Healthy Subjects in Cohort 4",
                    "description": "Healthy Subject randomized to 5040 mg AL001 daily \u00d7 14 days, given as 8 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 3,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG007",
                    "title": "Healthy Subjects in Cohort 5",
                    "description": "Healthy Subject randomized to 6300 mg AL001 daily \u00d7 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 \u00d7 210 mg AL001 capsules TID.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 6,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 6,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 6
                },
                {
                    "id": "EG008",
                    "title": "AD Subjects on Placebo",
                    "description": "Subjects w/AD randomized to Placebo across all Cohorts",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 8,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 8,
                    "otherNumAffected": 4,
                    "otherNumAtRisk": 8
                },
                {
                    "id": "EG009",
                    "title": "Healthy Subjects on Placebo",
                    "description": "Healthy Subjects randomized to Placebo in all Cohorts",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 8,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 8,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 8
                }
            ],
            "otherEvents": [
                {
                    "term": "Gastrointestinal",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Constipation, Abdominal discomfort/distention/pain, nausea, dyspepsia.",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 4,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 7,
                            "numAffected": 4,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 5,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 11,
                            "numAffected": 4,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 8,
                            "numAffected": 3,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Nervous System",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Headache",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 3,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 4,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Investigations",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Hepatic enzyme increased",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Renal and Urinary",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Pollakisuria",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Skin",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Hypopigmentation, Erythema",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Procedural complications",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Procedural dizziness",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Respiratory",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Rhinorrhea",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 4,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Psychiatric",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Insomnia",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Musculoskeletal",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Myalgia",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Ear Labyrinth",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Tinnitus",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Endocrine",
                    "organSystem": "Endocrine disorders",
                    "sourceVocabulary": "MedDRA 25.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Hypothyroidism",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG003",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG004",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG005",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG006",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG007",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 6
                        },
                        {
                            "groupId": "EG008",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG009",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "LTE60",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Eve Del Rio, MD, PhD",
                "organization": "Alzamend Inc.",
                "email": "Eve@RioPharma.com",
                "phone": "9736993847"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "AL001 (lithium-salicylate-L\u2011proline ionic cocrystal \u2014 a lithium delivery system; a LiProSal formulation)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The MAD study description and registry list AL001 as a crystal\u2011engineered lithium-salicylate\u2011proline lithium delivery product developed to treat dementia related to Alzheimer\u2019s disease \u2014 i.e., an oral lithium formulation intended as a therapeutic for AD rather than a biologic or purely symptomatic cognitive enhancer. \ue200cite\ue202turn1search2\ue202turn1search1\ue201",
        "Act: Key details \u2014 Phase 1/2a multiple ascending dose, placebo-controlled study of AL001 in mild\u2013moderate AD and healthy subjects. AL001 is described by the sponsor (Alzamend) as a patented ionic cocrystal lithium delivery system (LiProSal) designed to deliver lithium to the brain with improved safety/biodistribution versus marketed lithium salts. These sources identify AL001 as a small\u2011molecule/ionic formulation (not a monoclonal antibody or other biologic). Classification: disease-targeted small molecule. \ue200cite\ue202turn1search2\ue202turn1search3\ue201",
        "Reflect: Check for ambiguity \u2014 note that the name \u201cAL001\u201d is also used by another company (Alector) for a sortilin\u2011targeting monoclonal antibody in neurodegeneration, so it\u2019s important to match the trial sponsor/registry to disambiguate. The provided trial title and registry entry correspond to Alzamend\u2019s lithium ionic\u2011cocrystal AL001, so the small\u2011molecule classification is appropriate here. \ue200cite\ue202turn0search3\ue202turn1search2\ue201"
    ],
    "agent_type": "B) Tau",
    "explanation_agent": [
        "Reason: The trial drug AL001 is a lithium\u2011delivery ionic cocrystal (LiProSal) being developed as an oral therapeutic for Alzheimer\u2019s disease; the intended disease mechanism for lithium in AD is primarily through inhibition of glycogen synthase kinase\u20113 (GSK\u20113), which reduces tau hyperphosphorylation \u2014 linking lithium\u2019s action to tau pathology. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn1search6\ue201",
        "Act: Extracted details \u2014 AL001 is described by the sponsor (Alzamend) as a patented lithium\u2011salicylate\u2011L\u2011proline ionic cocrystal (a lithium delivery system) under clinical evaluation in mild\u2013moderate AD and healthy subjects; it is a small\u2011molecule/ionic formulation (not a biologic). Lithium\u2019s documented biochemical effect includes reducing GSK\u20113 activity and lowering tau phosphorylation in experimental models, which is why lithium\u2011based therapies are considered to act on tau pathology. Based on those specifics, the best CADRO match is B) Tau. \ue200cite\ue202turn2search5\ue202turn0search3\ue202turn1search0\ue201",
        "Reflect: Confirmation and caveats \u2014 This classification assumes the therapeutic rationale for AL001 is to deliver lithium to the brain to act on pathways (notably GSK\u20113/tau) relevant to AD. AL001\u2019s formulation and trial descriptions from sponsor/registry materials identify it as a lithium delivery small molecule (not multi\u2011target biologic). Although lithium has multiple cellular effects (including potential effects on amyloid processing, synaptic function, autophagy, and neuroprotection), the most specific CADRO category that matches the primary mechanistic rationale cited for lithium in AD (inhibiting GSK\u20113 and reducing tau phosphorylation) is B) Tau. If the sponsor\u2019s explicit primary mechanism in later documentation emphasized a different pathway (e.g., primarily neuroprotection or multi-mechanistic claims), R) Multi-target or another category might be considered. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn1search3\ue201",
        "Web search results (key sources used):",
        "- Alzamend press release & trial description: initiation and MAD study description for AL001 (lithium\u2011salicylate\u2011L\u2011proline ionic cocrystal). \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "- Alzamend product pipeline page describing AL001 / LiProSal as a lithium ionic cocrystal (small\u2011molecule lithium delivery system). \ue200cite\ue202turn2search5\ue201",
        "- Preclinical/experimental literature showing lithium inhibits GSK\u20113 and reduces tau phosphorylation in neuronal and transgenic models. \ue200cite\ue202turn1search6\ue202turn1search0\ue201"
    ]
}